MX2023002900A - Derivados de 2-(3-piridin-2-il-4-quinolin-4-il-pirazol-1-il)-aceta mida como inhibidores del receptor i del factor de crecimiento transformante beta/cinasa 5 similar al receptor de activina (alk5). - Google Patents
Derivados de 2-(3-piridin-2-il-4-quinolin-4-il-pirazol-1-il)-aceta mida como inhibidores del receptor i del factor de crecimiento transformante beta/cinasa 5 similar al receptor de activina (alk5).Info
- Publication number
- MX2023002900A MX2023002900A MX2023002900A MX2023002900A MX2023002900A MX 2023002900 A MX2023002900 A MX 2023002900A MX 2023002900 A MX2023002900 A MX 2023002900A MX 2023002900 A MX2023002900 A MX 2023002900A MX 2023002900 A MX2023002900 A MX 2023002900A
- Authority
- MX
- Mexico
- Prior art keywords
- alk5
- growth factor
- transforming growth
- quinolin
- pyrazol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20382861.1A EP3978487A1 (en) | 2020-09-30 | 2020-09-30 | 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)-acetamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5 |
| PCT/EP2021/076730 WO2022069509A1 (en) | 2020-09-30 | 2021-09-29 | 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)-acetamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023002900A true MX2023002900A (es) | 2023-05-25 |
Family
ID=72744716
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023002900A MX2023002900A (es) | 2020-09-30 | 2021-09-29 | Derivados de 2-(3-piridin-2-il-4-quinolin-4-il-pirazol-1-il)-aceta mida como inhibidores del receptor i del factor de crecimiento transformante beta/cinasa 5 similar al receptor de activina (alk5). |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US12577230B2 (https=) |
| EP (2) | EP3978487A1 (https=) |
| JP (1) | JP7752684B2 (https=) |
| KR (1) | KR20230079027A (https=) |
| CN (1) | CN116323601A (https=) |
| AR (1) | AR123543A1 (https=) |
| AU (1) | AU2021353965A1 (https=) |
| BR (1) | BR112023004612A2 (https=) |
| CA (1) | CA3196108A1 (https=) |
| ES (1) | ES3029607T1 (https=) |
| IL (1) | IL301663B1 (https=) |
| MX (1) | MX2023002900A (https=) |
| PH (1) | PH12023550777A1 (https=) |
| WO (1) | WO2022069509A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021105317A1 (en) | 2019-11-28 | 2021-06-03 | Origo Biopharma, S.L. | Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5 |
| WO2026017797A1 (en) | 2024-07-17 | 2026-01-22 | Agomab Spain S.L.U. | Crystalline forms |
| WO2026082960A1 (en) | 2024-10-18 | 2026-04-23 | Agomab Therapeutics Nv | 1,5-naphtyridine and quinoline based inhibitors of alk5 |
| WO2026082968A1 (en) | 2024-10-18 | 2026-04-23 | Agomab Therapeutics Nv | Novel compounds |
| CN121554469B (zh) * | 2026-01-23 | 2026-04-17 | 四川大学华西医院 | 一种alk5 protac化合物及其应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6514977B1 (en) * | 1997-05-22 | 2003-02-04 | G.D. Searle & Company | Substituted pyrazoles as p38 kinase inhibitors |
| AU754830C (en) * | 1997-05-22 | 2004-02-12 | G.D. Searle Llc | Substituted pyrazoles as p38 kinase inhibitors |
| ATE291020T1 (de) * | 2001-02-02 | 2005-04-15 | Smithkline Beecham Corp | Pyrazolderivate gegen tgf überexprimierung |
| CA2496295C (en) | 2002-09-18 | 2010-11-23 | Michael John Munchhof | Novels pyrazole compounds as transforming growth factor (tgf) inhibitors |
| WO2004026302A1 (en) | 2002-09-19 | 2004-04-01 | Eli Lilly And Company | Methods of inhibiting tgf beta with substituted pyrazoles |
| CL2004000234A1 (es) | 2003-02-12 | 2005-04-15 | Biogen Idec Inc | Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid |
| WO2007005951A2 (en) * | 2005-07-05 | 2007-01-11 | Aryx Therapeutics, Inc. | Stereoisomeric pyridyl and pyridonyl compounds and methods for the treatment of gastrointestinal and central nervous system disorders |
| CA2720343A1 (en) * | 2008-04-04 | 2009-10-08 | Takeda Pharmaceutical Company Limited | Heterocyclic derivative and use thereof |
| US8937150B2 (en) | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
| CN102762551A (zh) | 2009-12-21 | 2012-10-31 | 拜尔农作物科学股份公司 | 噻吩基吡(嘧)啶基吡唑及其用于防治植物致病菌的用途 |
| AU2012281281B2 (en) * | 2011-07-13 | 2017-06-01 | Tiumbio Co., Ltd | 2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors |
| EP2766347B1 (en) | 2011-10-14 | 2016-05-04 | Bristol-Myers Squibb Company | Substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
| WO2016172631A2 (en) | 2015-04-24 | 2016-10-27 | President And Fellows Of Harvard College | Substrate selective inhibitors of insulin-degrading enzyme (ide) and uses thereof |
| US20210002265A1 (en) | 2018-03-02 | 2021-01-07 | Université de Lausanne | Pyrazole derivatives as inhibitors of the wnt signalling pathway |
| US11945803B2 (en) | 2018-08-07 | 2024-04-02 | Tosk, Inc. | Modulators of RAS GTPase |
| CN110433164A (zh) | 2019-08-15 | 2019-11-12 | 南开大学 | TGF-beta受体分子抑制剂在治疗小鼠动物模型中急性髓系白血病的应用 |
| WO2021105317A1 (en) | 2019-11-28 | 2021-06-03 | Origo Biopharma, S.L. | Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5 |
-
2020
- 2020-09-30 EP EP20382861.1A patent/EP3978487A1/en not_active Withdrawn
-
2021
- 2021-09-17 AR ARP210102591A patent/AR123543A1/es unknown
- 2021-09-29 BR BR112023004612A patent/BR112023004612A2/pt unknown
- 2021-09-29 PH PH1/2023/550777A patent/PH12023550777A1/en unknown
- 2021-09-29 ES ES21786169T patent/ES3029607T1/es active Pending
- 2021-09-29 CN CN202180066883.4A patent/CN116323601A/zh active Pending
- 2021-09-29 MX MX2023002900A patent/MX2023002900A/es unknown
- 2021-09-29 IL IL301663A patent/IL301663B1/en unknown
- 2021-09-29 WO PCT/EP2021/076730 patent/WO2022069509A1/en not_active Ceased
- 2021-09-29 CA CA3196108A patent/CA3196108A1/en active Pending
- 2021-09-29 AU AU2021353965A patent/AU2021353965A1/en active Pending
- 2021-09-29 KR KR1020237008242A patent/KR20230079027A/ko active Pending
- 2021-09-29 EP EP21786169.9A patent/EP4222149B1/en active Active
- 2021-09-29 US US18/246,903 patent/US12577230B2/en active Active
- 2021-09-29 JP JP2023519608A patent/JP7752684B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AR123543A1 (es) | 2022-12-14 |
| CA3196108A1 (en) | 2022-04-07 |
| IL301663B1 (en) | 2026-01-01 |
| JP7752684B2 (ja) | 2025-10-10 |
| AU2021353965A9 (en) | 2024-08-01 |
| ES3029607T1 (en) | 2025-06-24 |
| EP4222149A1 (en) | 2023-08-09 |
| US12577230B2 (en) | 2026-03-17 |
| BR112023004612A2 (pt) | 2023-04-11 |
| US20230373966A1 (en) | 2023-11-23 |
| EP4222149B1 (en) | 2026-05-06 |
| IL301663A (en) | 2023-05-01 |
| KR20230079027A (ko) | 2023-06-05 |
| JP2023544716A (ja) | 2023-10-25 |
| CN116323601A (zh) | 2023-06-23 |
| AU2021353965A1 (en) | 2023-04-27 |
| WO2022069509A1 (en) | 2022-04-07 |
| EP3978487A1 (en) | 2022-04-06 |
| PH12023550777A1 (en) | 2023-11-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12023550777A1 (en) | 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)- acetamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5 | |
| GEAP202315746A (en) | Protein tyrosine phosphatase inhibitors | |
| MX2022010011A (es) | Inhibidores de prmt5 novedosos. | |
| MX2023009222A (es) | Inhibidores tricíclicos-amido-bicíclicos de prmt5. | |
| MX2023007218A (es) | Cocristal de un inhibidor de cinasa dependiente de ciclina (cdk). | |
| PH12021550825A1 (en) | Quinoline derivatives as alpha4beta7 integrin inhibitors | |
| GEP20257823B (en) | Amino quinazoline derivatives as p2x3 inhibitors | |
| PH12020550881A1 (en) | Substituted bicyclic heterocyclic compounds as prmt5 inhibitors | |
| MY195576A (en) | Novel Amino-Imidazopyridine Derivatives as Janus Kinase Inhibitors and Pharmaceutical use Thereof | |
| MX2022004878A (es) | Derivados de n-(heteroaril)quinazolin-2-amina a manera de inhibidores de lrrk2, composiciones farmaceuticas y usos de los mismos. | |
| WO2019168688A3 (en) | Quinolone analogs and their salts, compositions, and method for their use | |
| MX2023010087A (es) | Derivados heterociclicos como inhibidores de cinasas jano. | |
| MY206262A (en) | Macrocyclic tyrosine kinase inhibitor and uses thereof | |
| ZA202205149B (en) | Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5 | |
| WO2022268935A3 (en) | Process for the preparation of nlrp3 inhibitors | |
| MX2020007985A (es) | Inhibicion del canal ionico receptor de potencial transitorio a1. | |
| MX2023010083A (es) | Derivados heterociclicos como inhibidores de cinasas jano. | |
| MX2025011499A (es) | Forma de cristal de sal de compuesto de anillo fusionado cuaternario, y método de preparación y uso del mismo | |
| MX2019014321A (es) | Compuestos biciclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias. | |
| AU2021260669A8 (en) | A formulation for treating ophthalmic conditions | |
| MX2023005805A (es) | Derivados de 4-aminas de (aza)quinolina como inhibidores del purinorreceptor 3 p2x (p2x3). | |
| MX2024003930A (es) | Moduladores de trpml, sus composiciones y metodos de uso. | |
| PH12022550895A1 (en) | Compositions for preventing or treating chronic obstructive pulmonary diseases (copd) | |
| MX2025003410A (es) | Inhibidores de la quinasa 7 dependiente de ciclina | |
| JOP20180057A1 (ar) | مركبات رابع هيدروبيريدو بيرازين والتي تعمل كمعدلات gpr6 |